Orchestra BioMed insider purchase: 6,000 shares acquired by CEO
Rhea-AI Filing Summary
David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), reported purchasing a total of 6,000 shares of the company's common stock on 08/21/2025 at a weighted-average price of $2.49 per share (individual trade prices ranged from $2.49 to $2.50). After the reported purchase, Mr. Hochman beneficially owns 651,460 shares directly and additional shares indirectly via multiple family trusts (total indirect positions listed: 449,331; 2,000; 2,000; 2,000; 3,140). The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing discloses insider buying by the CEO/chair but does not provide reasons for the transactions.
Positive
- Insider purchase reported: CEO/chair acquired 6,000 shares on 08/21/2025 at a weighted-average price of $2.49.
- Substantial insider ownership remains: Reporting person holds 651,460 shares directly and meaningful indirect trust holdings, indicating alignment with shareholders.
Negative
- None.
Insights
TL;DR: CEO and chair purchased a small number of shares, modestly increasing his direct stake, which signals insider confidence but is not a material shift.
The acquisition of 6,000 shares by the CEO/chair at about $2.49 per share is a standard insider purchase disclosed on Form 4. The filing shows substantial existing ownership (over 651k shares directly plus meaningful indirect trust holdings), indicating long-standing insider alignment with shareholders. The transaction size is modest relative to total holdings, so while it is a supportive signal, it is unlikely to materially affect control or valuation.
TL;DR: Insider buying is a positive behavioral signal but small relative to reported ownership; limited direct market impact.
The reported weighted-average purchase price range ($2.49–$2.50) and the 6,000-share size are fully disclosed and routine. The incremental purchase increases direct beneficial ownership to 651,460 shares but represents a small percentage change versus that base. No derivative transactions or sales are reported. From a market-impact perspective, this disclosure is informational but not material in isolation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, par value $0.0001 per share ("Common Stock") | 6,000 | $2.49 | $15K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.50. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
FAQ
What did OBIO insider David P. Hochman report on Form 4?
Was the Form 4 signed and when?
Did the filing disclose any derivative transactions or sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.
